New codes for in-vitro diagnostics added to the Belgian Nomenclature


Mar 2023

On March 1, 2023, Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV) updated three Articles of the Nomenclature related to in-vitro diagnostics.

Eight new codes with corresponding conditions of reimbursement were added to Article 24 “Clinical biology” (Biologie Clinique). Fees in this Article are typically reimbursed at a 25% level (with some exceptions, e.g., a 100% fee is paid to subcontractor laboratories). Some examples of newly introduced codes are presented below:

  • 545930 - 545941 “Placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) assay with the calculation of the ratio sFlt-1/PlGF”;
  • 552495 - 552506 “Use of viscoelastic tests in the diagnosis and follow-up of hemorrhages caused either by severe trauma, or in obstetrics and postpartum, or during liver disease, liver transplantation, or cardiac surgery”;
  • 552510 - 552521 “Quantitation of anti-PR3 or anti-MPO antibodies in patients with clinical signs of possible ANCA-associated vasculitis who do not have a diagnosis of ANCA-associated vasculitis”.

Three new codes with corresponding conditions of reimbursement were added to Article 24bis “Clinical biology” (Biologie Clinique), §1 “Molecular biology tests on the genetic material of microorganisms”. Fees in this Article are reimbursed at a 100% level. An example of a newly introduced code is 557115 - 557126 “Detection of at least three respiratory infection agents using a molecular amplification technique.”

Moreover, one new code with corresponding conditions of reimbursement was implemented in Article 33bis “Genetic tests” (Examens Genetiques).

See more details in French here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news


Jun 2023

In the period of April-May 2023, the Galician Agency for Health Technology Assessment (AVALIA-T) initiated the five health technology assessments referred to IVD, nephrology and urology, obstetrics and gynecology, pulmonary and airways as well as surgical procedures technology groups. The assessments on stereotactic virtual navigation system for percutaneous puncture as well as tumor ablation and invasive telemonitoring of pulmonary pressure in patients with heart failure were released.

Read more


Jun 2023

In May 2023, the National Institute for Health and Care Excellence (NICE) published one new Interventional Procedure Guidance (intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure from high spinal cord injuries), two new Diagnostic Guidance (MRI fusion biopsy systems for diagnosing prostate cancer, automated ankle-brachial pressure index measurement devices to detect peripheral arterial disease), and three new Health Technology Evaluations (Digitally enabled therapies for adults with anxiety disorders / with depression, and point-of-care tests for urinary tract infections). Also, four clinical guidelines were updated.

Read more


Jun 2023

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in May 2023. Twenty-one recommendations were published in relation to the registration, modification of registration conditions, and renewal of registration for devices in the List of reimbursable products and services (LPPR). Opinions concern cardiovascular and peripheral vascular, endocrine, ENT, gastrointestinal, and orthopedic devices, as well as medical aids.

Read more


Jun 2023

On May 23, 2023, the Ministry of Health and Prevention published an Order in the Official Journal of the French Republic setting the tariffs for the medical telemonitoring activities covered by social health insurance in the context of the new framework. The tariffs will differ whether they bring an organizational or clinical (improvement in quality of life, morbidity, or mortality) benefit.

Read more


May 2023

On May 17, 2023, the Ministry of Health and Prevention published the 2023-2027 Digital Health Roadmap. The new roadmap specifies the priorities and the projects to be carried out by 2027. One of the key objectives is to support the implementation and extension of telemonitoring to more chronic pathologies.

Read more